Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature
Benedikt Schoser(Friedrich Baur Stiftung), Peter Young(NHS Ayrshire and Arran), Derralynn Hughes(Royal Free London NHS Foundation Trust), Edward Fong(Stanford University), Harm A.W.M. Tiddens(Erasmus MC), David Orlikowski(Hôpital Raymond-Poincaré), Mark Roberts(Sherwood Forest Hospitals NHS Foundation Trust), John T. Kissel(The Ohio State University), Tarekegn Geberhiwot(Selly Oak Hospital), Shyam Madathil(Queen Elizabeth Hospital Birmingham), Michael I. Polkey(University of Cambridge)
Cited by 109
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database
|PLoS Genetics|2012|543
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522
An official European Respiratory Society statement on physical activity in COPD
|European Respiratory Journal|2014|519
The prevalence of quadriceps weakness in COPD and the relationship with disease severity
|European Respiratory Journal|2009|486